A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,401–3,500 of 3,967
Zheng, P., Sun, S., Wang, J., Cheng, Z. J., Lei, K. C., Xue, M., Zhang, T., Huang, H., Zhang, X. D., & Sun, B. (2021) · Research Square · doi:10.21203/rs.3.rs-729282/v1
Sun, F., Wu, Z., Jiang, F., Huang, M., Wang, J., Sun, W., & Zhang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-772721/v1
Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease
Podolanczuk, A. J., & Martínez, F. J. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00375-1
Mechanotherapeutics for the Treatment of Idiopathic Pulmonary Fibrosis
Lagares, D., & Han, H. (2021) · Barcelona Respiratory Network · doi:10.23866/brnrev:2020-0012
Can acute exacerbations occurring late after surgery with interstitial lung diseases be predicted?
Ichinokawa, H., Takamochi, K., Nojiri, S., Fukui, M., Hattori, A., Matsunaga, T., & Suzuki, K. (2021) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-021-01707-0 · Cited by 1
Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis
Banudevi, S., & Bose, V. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_12
Zhou, I. Y., Montesi, S. B., Akam, E. A., & Caravan, P. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00077-6
An Introduction to Advanced Lung Disease
Jablonski, R. P., & Strek, M. E. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_2
【特集】特発性間質性肺炎の診療の現状と将来展望 特発性肺線維症に対する抗線維化薬の使い方
宏紀, 林., & 安良太, 吾. (2018) · Medical Entomology and Zoology · doi:10.24557/kokyurinsho.2.e00043
持続可能な地域おこしにむけて : 「観光」と「スポーツ」をつなぐ (特集 からだ : スポーツ・教育・科学・文化・芸術からのアプローチ)
大野, 哲. (2013) · Toin University of Yokohama Academic Repository · doi:10.50937/00000564
International Business: What Can We Do?.
Reynolds, J. K. (2002)
Advances with pharmacotherapy for the treatment of interstitial lung disease
Comes, A., Sgalla, G., Perrotta, A., & Richeldi, L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2016697
Idiopathic pulmonary fibrosis in the practice of a family doctor
Skvortsov, V. V., Zadumina, D. N., Skvortsova, E. M., & Tinaeva, E. M. (2022) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2201-05 · Cited by 1
Yang, X., Zhao, G., Bo, Y., Yang, D., Dong, Z., Wu, G., Xu, N., An, M., & Zhao, L. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3990206
Fainberg, H. P., Oldham, J. M., Molyneaux, P. L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000658
Induced pluripotent stem cells
Calvert, B. A., Lorenzana, Z., Senger, C. N., Hsu, C.-Y., Busch, S. M., Koç-Günel, S., Quiroz, E. J., & Ryan, A. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823882-0.00003-5
Pharmacological Management of Idiopathic Pulmonary Fibrosis
Panahi, L., Udeani, G., Tenpas, A. S., Ofili, T. U., Aguilar, E. M., Burchard, S., Ritenour, A., Chennat, A. J., Ahmed, N., Atphaisit, C., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101390
Grundlagen der medikamentösen Therapie
Drakopanagiotakis, F., & Günther, A. (2022) · Springer eBooks · doi:10.1007/978-3-662-63651-0_5
Hagmeyer, L., Kahn, N. C., Kirsten, A. M., & Kolb, M. R. J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63651-0_11
The Keys to Making a Confident Diagnosis of IPF
Sheth, J. S., Wadhwa, A., & Flaherty, K. R. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_12
Multiple Choice Questions with explanations
(2015) · European Respiratory Society eBooks · doi:10.1183/9781849840781-ch1
Anesthesia for Patients with End-Stage Lung Disease
Costescu, F., & Ma, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-00859-8_31
Navaratnam, V. V., Forrester, D. L., & Hubbard, R. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004615
Role of Progenitors in Pulmonary Fibrosis and Asthma
Banerjee, E. R., & Henderson, W. R. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-16232-4_5
Walsh, S. L. F. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10005215
Respiratory Organ Aging and Cancer
Witt, L. J., & Presley, C. J. (2020) · Springer eBooks · doi:10.1007/978-3-319-57415-8_63
Lung Organoids: A New Pathway into Lung Regeneration and Repair
Tian, L., Zhang, C. C., Rea-Moreno, M., & Chen, Y. (2022) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-030-93056-1_2
Understanding and Therapeutically Targeting the Scleroderma Myofibroblast
Ocon, A. J., Lokineni, S., & Korman, B. D. (2022) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-021-00189-8
[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis
Molina‐Molina, M., Buendía-Roldán, I., Castillo, D., Caro, F. M., Valenzuela, C., & Selman, M. (2022) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2021.12.017 · Cited by 1
Interstitielle Lungenerkrankungen
Behr, J. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-23814-7.00011-5
Traitement des atteintes systémiques de la maladie de Sjögren
Guern, V. L., & Bécel, G. (2022) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2022.04.004
Transbronchial cryobiospy in the diagnosis of ILD
Pradhan, R. (2018) · Pulmonary and Respiratory Medicine International Journal · doi:10.30881/prmij.00001
Markart, P., Drakopanagiotakis, F., Derugin, N., & Wygrecka, M. (2019) · Pneumo News · doi:10.1007/s15033-019-1300-0
Molyneaux, P. L., Nicholson, A. G., Hirani, N., & Wells, A. U. (2020) · doi:10.1093/med/9780198746690.003.0415
Acute Exacerbation of Interstitial Lung Disease
(2017) · Elsevier eBooks · doi:10.1016/b978-0-323-52477-3.50082-2
Milger, K., & Behr, J. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10008715
Faculty Opinions recommendation of Mesothelial cells in tissue repair and fibrosis.
Sassoon, D. A., & Valente, M. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725707960.793552095
Hagmeyer, L., & Kolb, M. R. J. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_11
Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Kumar, A., & Hadley, R. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_30
Common Co-Morbidities in Fibrosing Interstitial Lung Disease
Kahn, N. C., Torrisi, S. E., Somogyi, V., & Kreuter, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00019-6
Selected Disorders of the Respiratory System
Howlett, B. M., Coleman, G. C., Hoffman, R. H., et al. (2016) · Springer eBooks · doi:10.1007/978-3-319-04414-9_93
Interstitielle Lungenerkrankungen
Behr, J. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-24951-8.00018-x
Rheumatology Around The World … What is New?
(2015) · Egyptian Journal of Rheumatology & Clinical Immunology · doi:10.21608/ejrci.2015.9309
Interstitielle Lungenerkrankungen
Behr, J. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-24950-1.00028-7
Faculty Opinions recommendation of Therapeutic targets for treating fibrotic kidney diseases.
Chade, A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718555358.793552580
(2016) · European Respiratory Society eBooks · doi:10.1183/9781849840781.013
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734825206.793563347
Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Mejía, M. E., & Selman, M. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2018.09.012
Patterns of cardiopulmonary response to exercise in fibrotic ILD
Molgat‐Seon, Y., Guenette, J. A., Schaeffer, M. R., Ryerson, C. J., Marillier, M., Vergès, S., O’Donnell, D. E., & Neder, J. A. (2018) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020317 · Cited by 2
Rheumatoid Arthritis Interstitial Lung Disease
Matson, S. M., & Lee, J. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00022-6
Behr, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_376-1
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R. L., Sköld, C. M., Myllärniemi, M., & Murgia, G. (2019) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2018.140 · Cited by 1
Comprehensive Care of Interstitial Lung Disease
Wijsenbeek, M. S., & Moor, C. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11301-7 · Cited by 1
Elements: in this month's issue
Donnelly, S. C. (2014) · QJM · doi:10.1093/qjmed/hcu133
May 2014 Arizona thoracic society notes
Robbins, R. A. (2014) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc072-14
Pulmonary issues in the elderly
Austin, C. A., & Carson, S. S. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.021
Pickl, S. (2015) · Pneumo News · doi:10.1007/s15033-015-0173-0
Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease
Algamdi, M., Guler, S. A., & Ryerson, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11414-x
Selected Disorders of the Respiratory System
Howlett, B. M., Coleman, G. C., Hoffman, R. H., et al. (2015) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_93-1
Wittman, C., & Swigris, J. J. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_16
Self-citationWong, A. W., & Ryerson, C. J. (2020) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2020.1722040
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Jain, N. K., Jain, S., Mushtaq, H. A., Khedr, A., Koritala, T., Tekin, A., Adhikari, R., Sule, A. A., Gautam, S. C., Pattan, V., et al. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104610 · Cited by 1
Kohar, K., Andrew, H., & Gabrian, A. (2022) · SCRIPTA SCORE Scientific Medical Journal · doi:10.32734/scripta.v3i2.5390
Antifibrotic therapy and its indications for interstitial pulmonary fibrosis
Doubková, M. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.045
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
Föll, D., & Kallinich, T. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-60410-6_24
Formulated Herbal Medicines for Idiopathic Pulmonary Fibrosis: A Case SeriesPreprint
Chan, M.-Y., Man, S., Qin, Z., Ho, C.-M. J., Yan, S.-W., Yee, K.-S., Kwok, H.-C., Zhang, L.-B., Shen, S. Y., Chen, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4103300
Impact of Reduction in Antifibrotic Treatment on Mortality in Idiopathic Pulmonary FibrosisPreprint
Porse, S., Hoyer, N., & Shaker, S. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184350
Association Between Weight Loss and Mortality in Idiopathic Pulmonary FibrosisPreprint
Kalininskiy, A., Rackow, A. R., Nagel, D. J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1936563/v1
Witt, L. J., & Austin, C. A. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.022
A new chance to treat rheumatoid arthritis lung fibrosis?
Sebastiani, M., & Manfredi, A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00295-8
Durán, A. C., Oriol, A. J., & Bobillo, J. R. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.012
Indicaciones de trasplante pulmonar
Durán, D., Franquiz, W. B., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.013
Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen
Kreutz, C.-P., Gesierich, W., Behr, J., & Kneidinger, N. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1825-4967
Singh, H., Jankharia, B. G., Singh, S., Dhar, R., Gothi, D., Behera, D., Hadda, V., Talwar, D., Pilania, K., Desai, U. D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-62-2-73
Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.11.018
Fibroses pulmonaires : mise à jour des recommandations et nouveaux traitements
Bouvry, D. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00775-3
Pulmonary Fibrosis: One Manifestation, Various Diseases
Ruaro, B., Matucci‐Cerinic, M., Baratella, E., Confalonieri, M., Salton, F., & Hughes, M. (2022) · Frontiers research topics · doi:10.3389/978-2-83250-654-7
Organizing Pneumonia Versus Usual Interstitial Pneumonia
Mau, B., Johnson, L. N., & Xu, H. (2022) · Pracatical anatomic pathology · doi:10.1007/978-3-031-14402-8_40
Usual Interstitial Pneumonia Versus Nonspecific Interstitial Pneumonia
Lerma, L. A., Chandler, C. M., & Xu, H. (2022) · Pracatical anatomic pathology · doi:10.1007/978-3-031-14402-8_38
Transplantation pulmonaire pour pneumopathie interstitielle diffuse fibrosante
Mordant, P., Dauriat, G., Brugière, O., Borie, R., Crestani, B., & Reynaud‐Gaubert, M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.012
Pneumologie : ce qui a changé en 2022
Kolb, M., Lechartier, B., Aubert, J., & Daccord, C. (2023) · JMIG · doi:10.53738/revmed.2023.19.809-10.77
New Frontiers in Therapeutics for Interstitial Lung Diseases
MESFIN, N. M., Sangani, R. A., Shankar, D. A., & Reardon, C. C. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202206-1035rr
Fibroblast growth factors (FGFs) endocrines et fibrogenèse pulmonaire
Ghanem, M., Mailleux, A., & Crestani, B. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.018
New Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Yoo, H. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.2.64
Behr, J. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_376-2
Interstitial Pneumonia with Autoimmune Features
Sergew, A., Fischer, A., & Brown, K. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_15
Idiopathic Pulmonary Fibrosis and the Many Faces of UIP
Luppi, F., & Richeldi, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_32
Unclassifiable Interstitial Lung Disease
Guler, S. A., & Ryerson, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_38
Idiopathic interstitial pneumonias: Idiopathic pulmonary fibrosis
Higo, H. (2023) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.135.36
Kulkarni, T. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00312-1
An Introduction to Engineering and Modeling the Lung
Tanneberger, A. E., Weiss, D. J., & Magin, C. M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-26625-6_1 · Cited by 1
Mullor, M. M. G., Arenas-Jiménez, J. J., Vacas, A. U., García‐Manso, I. G., Pérez, J. L. P., Serra, N. S., & Sevila, R. G. (2023) · Radiología · doi:10.1016/j.rx.2023.03.002
Generoso, L. N., Assis, M. G., de Leucas, P. L. B., Luz, M. B., Moura, M. P., Silva, M. L. M., & Mancuzo, E. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3038904/v1
裕理, 竹., Sugimoto, N., Kobayashi, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3008938/v1
The Fatigue Severity Scale in Interstitial Lung Disease: An Energizing Endpoint
Wong, A. W., & Johannson, K. A. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202305-0919ed
van Zyl-Smit, R. N., Soin, G. K., & Calligaro, G. (2023) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2023.v29i2.803
Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians
Moolla, M. S., Doruyter, A., & Allwood, B. (2023) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2023.v29i2.1231
Veit, T., & Behr, J. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00525-w
Selcuk, Ö., & Uslu, B. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4584796
Prasad, J. D., & Snell, G. I. (2023) · Respirology · doi:10.1111/resp.14614
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.